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Loading of a 2-Chlorotrityl Chloride Resin with an Fmoc protected amino acid  
After swelling of 750 mg of a 2-chlorotrityl chloride resin (1.2 mmol chloride) in water-free DCM for 10 min, the first 
Fmoc protected amino acid (T-shape: 0.75 eq. fmoc-Tyr(tBu)-OH, i-shape: 0.75 eq. Fmoc-Stp(Boc3)-OH, U-
shape: 0.75 eq. Fmoc-Lys(fmoc)-OH and DIPEA (1.5 eq.) were added to the resin for 1 h. The reaction solvent 
was drained and a mixture of DCM/MeOH/DIPEA (80/15/5) was added twice for 10 min. After the removal of the 
reaction mixture, the resin was washed 5 times with DCM.  
About 30 mg of the resin were removed and dried to determine the loading of the resin. Therefore, an exact 
amount of resin was treated with 1 mL deprotection solution (20 % piperidine in DMF) for 1 h. Afterwards, the 
solution was diluted and absorption was measured at 301 nm. The loading was then calculated according to the 
equation: resin load [mmol/g] = (A*1000)/(m [mg]*7800*df) with df as dilution factor. 
The resin was treated twice with 20% piperidine in DMF and twice with 20 % piperidine DMF with 2% DBU to 
remove the fmoc protection group. Reaction progress was monitored by Kaiser test. Afterwards, the resin was 
washed with DMF, DCM and n-hexane and dried in vacuo. 
 
Syntheses of oligomers containing oleic acid  
The coupling procedure of oligomers containing oleic acid (OleA) was the same used for all oligomers (see 
description in main manuscript). The cleavage of the structures off the resin was performed by incubation with 
TFA–TIS–H2O 95 : 2.5 : 2.5 (10 mL g−1 resin cooled to 4 °C prior to addition) for 30 min. followed by  immediate 
precipitatation in 40 mL of pre-cooled MTBE–n-hexane 1 : 1. The oleic acid containing oligomers were then 
purified by size exclusion chromatography using an Äkta purifier system (GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden), a Sephadex G-10 column and 10 mM hydrochloric acid solution–acetonitrile 7 : 3 as solvent. 
The oligomers were lyophilized. Oligomer sequences were validated by mass spectrometry and 1H-NMR. 
 
siRNA polyplex stability in 90% serum  
Polyplexes were formed using 2.5 µg siRNA in 6.25 µL HBG mixed with the oligomer at N/P 12 resulting in a total 
volume of 12.5 µL. Afterward the incubation 112.5 µl fetal bovine serum (FBS) was added to the samples. All 
samples had a final concentration of 90 % FBS. The samples were incubated at 37 °C for 2 h. 20 µL of the 
samples and 4 µL loading buffer were carefully mixed and a siRNA binding assay (see main manuscript) was 
performed. 
 
Particle Size and Zeta Potential 
For dynamic light scattering (DLS) measurements the polyplex solution was measured in a folded capillary cell 
(DTS 1070) using a Zetasizer Nano ZS with backscatter detection (Malvern Instruments, Worcestershire, UK). 
Polyplexes were formed using 1.5 µg siRNA in 30 µL HBG mixed with the oligomer at N/P 12 resulting in a total 
volume of 60 µL. For size measurements, the equilibration time was 0 min, the temperature was 25 °C and an 
automatic attenuator was used. The refractive index of the solvent was 1.330 and the viscosity was 0.8872 mPa•s. 
Each sample was measured 3 times. For zeta potential measurements, the sample was diluted to 800 µL with 
20 mM HEPES buffer. Zeta potentials were calculated by the Smoluchowski equation. Ten to fifteen sub runs 





The oligomers containing ssbb elements were diluted to a concentration of 1.67 mg/mL. 30 µL of the solution was 
mixed with 170 µL working solution (2.44 mL Ellman´s buffer (0.2 M Na2HPO4, 1 mM EDTA, pH 8.0) and 60 µL 
DTNB solution in methanol (c = 4 mg/mL)). After 15 min incubation at 37 °C absorption was measured at 412 nm 
using a GENESYSTM UV-VIS spectrophotometer (Thermo Scientific). The percentage of free mercapto groups is 
based on the theoretical amount (100 %) of thiols in case of complete cleavage. 
 
Proton 1H NMR spectroscopy 
1H NMR spectra were recorded using an AVANCE III HD 500 (500 MHz) by Bruker with a 5 mm CPPBBO probe. 
All spectra were recorded without TMS as internal standard and therefore all signals were calibrated to the 
residual proton signal of the deuterium oxide (D2O) solvent, or chloroform-d (CDCl3). Chemical shifts are reported 
in ppm and refer to the solvent as internal standard (D2O at 4.79; CDCl3 at 4.87). Integration was performed 
manually. The spectra were analyzed using MestreNova (Ver. 9.0 by MestReLab Research). 
 
MALDI Mass spectrometry 
One μL matrix droplet consisting of a saturated solution of Super-DHB (sum of 2,5-dihydroxybenzoic acid and 2-
hydroxy-5-methoxybenzoic acid) in acetonitrile / water (1 : 1) containing 0.1 % (v/v) TFA was spotted on a MTP 
AnchorChip (Bruker Daltonics, Bremen, Germany). After the Super-DHB matrix crystallized, one µL of the sample 
solution (10 mg/mL in water) was added to the matrix spot. Samples were analyzed using an Autoflex II mass 












Fig. S1 Sequence-defined oligomers with i-shape and U-shape topology. Schematic overview of 
the structures with different modifications (K: lysine, H: histidine, Stp: succinoyl-tetraethylene-






Fig. S2 siRNA binding ability of T-shape structures analyzed with an agarose gel shift assay. The 
left lane shows the running distance of free siRNA in HBG that is not complexed by lipo-
oligomers. Polyplexes were tested for siRNA binding ability at different N/P ratios. Top: stable  




Fig. S3 siRNA binding ability of i-shape and U-shape structures analyzed with an agarose gel 
shift assay. The left lane shows the running distance of free siRNA in HBG that is not complexed 
by lipo-oligomers. Polyplexes were tested for siRNA binding ability at different N/P ratios. Top: 






Fig. S4 Gel retardation assay of siRNA polyplexes incubated at N/P 12 for 40 min, followed by 
treatment with 90 % full serum for two hours at 37 °C. The black arrow points at a band that is 
caused by serum (see serum blank in band one). Running distance of free siRNA in HBG buffer 






Fig. S5 siRNA binding ability of T-shape structures under reducing conditions analyzed with an 
agarose gel shift assay. The left lane shows the running distance of free siRNA in HBG that is not 
complexed by lipo-oligomers. Lipopolyplexes were formed at N/P 20 followed by 90 min treatment 
at 37 °C with different concentrations of GSH in HEPES buffer pH 7.4. Top: stable structures, 
bottom: reducible structures. 
 
 
Fig. S6 siRNA binding ability of i-shape and U-shape structures under reducing conditions 
analyzed with an agarose gel shift assay. The left lane shows the running distance of free siRNA 
in HBG that is not complexed by lipo-oligomers. Lipopolyplexes were formed at N/P 20 followed 
by 90 min treatment at 37 °C with different concentrations of GSH in HEPES buffer pH 7.4. Top: 





Fig. S7 Gene silencing of i-shape and U-shape oligomers in neuroblastoma cells. Lipopolyplexes 
with 500 ng / 37 pmol eGFP-targeted siRNA (siGFP) / well respectively control siRNA (siCtrl) at 
N/P 6, 12 and 20 were tested for eGFPLuc gene silencing in Neuro2A/eGFPLuc cells. A) 
Lipopolyplexes made of stable structures 871 and 783 B) Lipopolyplexes made of bioreducible 
structures 969 and 782. The luciferase activity of siRNA treated cells is presented related to 
buffer-treated cells. HBG-treated cells were set to 100 %. Data are presented as mean value 






Fig. S8 Dose-dependent gene silencing of T-shape oligomers at N/P 12 in neuroblastoma cells. 
Lipopolyplexes with eGFP-targeted siRNA (siGFP) respectively control siRNA (siCtrl) were 
examined for eGFPLuc gene silencing in Neuro2A/eGFPLuc cells. The oligomer amount was 
adjusted for each formulation to keep it constant at N/P 12. Formulations including siRNA from 6, 
12, 27, 47, 93, 185, 370 up to 740 nM were tested. A) Lipopolyplexes made of stable structures 
1081 and 991 B) Lipopolyplexes made of bioreducible structures 1082 and 992. The luciferase 
activity of siRNA treated cells is presented related to buffer-treated cells. HBG-treated cells were 





Fig. S9 Dose-dependent gene silencing of T-shape oligomers in neuroblastoma cells. 
Lipopolyplexes with eGFP-targeted siRNA (siGFP) respectively control siRNA (siCtrl) at constant 
oligomer amount of 1.44 nmol (N/P 12 at 500 ng siRNA) were examined for eGFPLuc gene 
silencing in Neuro2A/eGFPLuc cells. Formulations including siRNA from 6, 12, 27, 47, 93, 185, 
370 up to 740 nM were tested. A) Lipopolyplexes made of stable structures 1081 and 991   B) 
Lipopolyplexes made of bioreducible structures 1082 and 992. The luciferase activity of siRNA-
treated cells is presented related to buffer-treated cells. HBG-treated cells were set to 100 %. 








Fig. S10 Gene silencing of T-shape oligomers in prostate cancer cells. Lipopolyplexes with 
500 ng eGFP-targeted siRNA (siGFP) respectively control siRNA (siCtrl) at N/P 12 were tested 
for eGFPLuc gene silencing in DU145/eGFPLuc cells. Lipopolyplexes made of stable structures 
(1081, 989 and 991) and bioreducible structures (1082, 990 and 992) are shown. The luciferase 
activity of siRNA treated cells is presented related to buffer-treated cells. HBG-treated cells were 




Fig. S11 Gene silencing of oleic acid containing T-shape oligomers in neuroblastoma cells. 
Lipopolyplexes with 500 ng / 37 pmol eGFP-targeted siRNA (siGFP) / well respectively control 
siRNA (siCtrl) at N/P 6, 12 and 20 were tested for eGFPLuc gene silencing in Neuro2A/eGFPLuc 
cells. The luciferase activity of siRNA treated cells is presented related to buffer-treated cells. 







Table S1 Determination of free thiols in reducible T-shape, i-shape and U-shape structures via 
Ellman´s assay 
Oligomer Ratio of free thiols (in %) 
1082 (MyrA-ss-t) 2.0 
990 (SteA-ss-t) 2.3 
992 (CholA-ss-t) 2.7 
969 (CholA-ss-i) 1.2 





Table S2 Particle size (Z-average) and zeta potential of siRNA polyplexes determined with a DLS 
zetasizer 
Oligomer N/P z-average [nm] Mean PDI Mean Zeta 
Potentianl [mV] 
1081 (MyrA-t) 12 105 ± 1,76 0,15 ± 0 27 ± 0,75 
1082 (MyrA-ss-t) 12 107,7 ± 0,53 0,14 ± 0,02 28,6 ± 0,75 
989 (SteA-t) 12 125,3 ± 1,03 0,12 ± 0,01 29,3 ± 1,6 
990 (SteA-ss-t) 12 137,9 ± 1,57 0,13 ± 0,01 26,8 ± 0,85 
991 (CholA-t) 12 131,7 ± 0,45 0,13 ± 0 29,4 ± 4,16 
992 (CholA-ss-t) 12 128,3 ± 0,5 0,13 ± 0,01 30,9 ± 0,72 
871 (CholA-i) 12 275 ± 7,22 0,24 ± 0,01 23,4 ± 0,68 
969 (CholA-ss-i) 12 237,8 ± 4,21 0,2 ± 0,01 25,2 ± 0,32 
783 (CholA-u) 12 122,7 ± 2,01 0,26 ± 0,02 31,53 ± 0,67 









Mass spectra of oligomers 
 
Summarizing table Mass data recorded with a Bruker MALDI-TOF instrument 
Oligomer Molecular formula [M+H]+ calc. [M+H]+ found 
1081 (MyrA-t) C144H235N31O26 2815.8 2813.6 
1082 (MyrA-ss-t) C152H249N33O28S2 3049.9 3048.2 
989 (SteA-t) C152H251N31O26 2927.9 2929.3 
990 (SteA-ss-t) C160H265N33O28S2 3162.0 3163.6 
991 (CholA-t) C164H259N31O26 3080.0 3079.0 
992 (CholA-ss-t) C172H273N33O28S2 3314.0 3314.2 
1107 (OleA-t) C152H247N31O26 2923.9 2922.9 
1108 (OleA-ss-t) C160H261N33O28S2 3158.0 3156.3 
871 (CholA-i) C138H232N40O18 2738.9 2739.2 
969 (CholA-ss-i) C146H246N42O20S2 2972.9 2973.2 
783 (CholA-u) C132H252N34O17 2587.0 2587.2 
782 (CholA-ss-u) C148H280N38O21S4 3055.0 3056.1 






































































































1H Proton NMR Spectra:  
 
 




1-(9H-fluoren-9-yl)-3,12-dioxo-2-oxa-7,8-dithia-4,11-diazapentadecan-15-oic acid (ssbb)  1H NMR (500 MHz, 
Methanol-d4) δ (ppm)  7.81 (d, J = 7.5 Hz, Ha, 2H), 7.67 (d, J = 7.4 Hz, Hb, 2H), 7.41 (t, J = 7.4 Hz, Hc,  2H), 
7.33 (t, J = 7.4 Hz, Hd, 2H), 4.38 (d, J = 6.9 Hz, He, 2H), 4.22 (t, J = 6.8 Hz, Hf, 1H), 3.49 (t, J = 6.7 Hz, Hg, 2H), 











1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 myristic acid), 0.85-2.30 (m, 56 H, βγδH 
lysine, myristic acid), 2.3-2.6 (m, 20 H, -CO-CH2-CH2-CO- Stp, -CO-CH2- myristic acid), 2.6-3.10 (m, 16 H, εH 






Sequence (C→N): Y3-Stp2-K-ε[G-ssbb-K-α,ε(MyrA)2]αStp2-Y3 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.80 (s, 6 H, -CH3 myristic acid), 0.80-2.25 (m, 56 H, βγδH 
lysine, myristic acid), 2.3-2.6 (m, 24 H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- myristic acid), 2.60-3.05 (m, 
24 H, εH lysine and tyrosine, -CH2- ssbb), 3.05-3.60 (m, 64 H, -CH2- Tp), 3.65-4.55 (m, 10 H, αH amino acids), 










1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.65-0.85 (s, 6 H, -CH3 stearic acid), 0.85-2.25 (m, 76 H, βγδH 
lysine, -CH2- stearic acid), 2.3-2.65 (m, 20 H, -CO-CH2-CH2-CO- Stp, -CO-CH2- stearic acid), 2.65-3.1 (m, 16 H, 











1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.50-2.25 (m, 82 H, βγδH lysine, -CH2- and -CH3 stearic acid), 
2.3-2.6 (m, 24 H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- stearic acid), 2.6-3.1 (m, 24 H, εH lysine and 





Sequence (C→N): Y3-Stp2-K-ε[G-K-α,ε(CholA)2]αStp2-Y3 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.35-2.20 (m, 88 H, βγδH lysine, cholanic acid), 2.2-2.6 (m, 20 
H, -CO-CH2-CH2-CO- Stp, -CO-CH2- cholanic acid), 2.6-3.05 (m, 16 H, εH lysine and tyrosine), 3.05-3.60 (m, 64 






Sequence (C→N): Y3-Stp2-K-ε[G-ssbb-K-α,ε(CholA)2]αStp2-Y3 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.40-2.30 (m, 88 H, βγδH lysine, cholanic acid), 2.3-2.7 (m, 24 
H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- cholanic acid), 2.70-3.15 (m, 24 H, εH lysine and tyrosine, -CH2- 









1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 (m, 72 H, βγδH 
lysine, -CH2- oleic acid), 2.25-2.60 (m, 20 H, -CO-CH2-CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 16 H, εH 
lysine and tyrosine), 3.1-3.65 (m, 64 H, -CH2- Tp), 3.70-4.55 (m, 10 H, αH amino acids), 5.05 – 5.25  (s, 4 H,  



































1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.80 (s, 6 H, -CH3 oleic acid), 0.85-2.10 (m, 72 H, βγδH 
lysine, -CH2- oleic acid), 2.25-2.60 (m, 22 H, -CO-CH2-CH2-CO- Stp, -CO-CH2- oleic acid), 2.60-3.0 (m, 22 H, εH 
lysine and tyrosine), 3.05-3.65 (m, 64 H, -CH2- Tp), 3.70-4.60 (m, 10 H, αH amino acids), 5.00 – 5.25  (s, 4 H,  




Sequence (C→N): K-αK-α,ε[Stp3-ssbb-(CholA)2]2 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.45-2.40 m, 88 H, βγδH lysine, cholanic acid), 2.40-2.60 (m, 36 
H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- cholanic acid), 2.65-3.15 (m, 12 H, εH lysine, -CH2- ssbb), 3.15-






Sequence (C→N): K-αK-α,ε[Stp3-(CholA)2]2 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.50-2.35 m, 88 H, βγδH lysine, cholanic acid), 2.40-2.60 (m, 28 
H, -CO-CH2-CH2-CO- Stp, -CO-CH2- cholanic acid), 2.85-3.15 (m, 4 H, εH lysine), 3.15-3.65 (m, 96 H, -CH2- 





Sequence (C→N): Stp4-H6-K-α,ε(CholA)2 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.40-2.30 m, 82 H, βγδH lysine, cholanic acid), 2.40-2.55 (m, 20 
H, -CO-CH2-CH2-CO- Stp, -CO-CH2- cholanic acid), 2.55-3.05 (m, 14 H, εH lysine and histidine), 3.05-3.60 (m, 
64 H, -CH2- Tp), 3.95-4.65 (m, 7 H, αH lysines and histidines), 7.10-7.35 (d, 6 H, aromatic H histidine), 8.5-8.65 









1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.40-2.30 m, 82 H, βγδH lysine, cholanic acid), 2.30-2.55 (m, 24 
H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- cholanic acid), 2.55-3.15 (m, 22 H, εH lysine and histidine, -CH2- 
ssbb), 3.15-3.65 (m, 64 H, -CH2- Tp), 3.75-4.65 (m, 7 H, αH lysines and histidines), 7.10-7.35 (d, 6 H, aromatic H 




740 (test structure): 




1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.95 (m, 18 H, δH leucine), 1.10-1.60 (m, 12 H, βγH 
leucine), 2.20-2.50 (m, 12 H, -CO-CH2-CH2-CO- Stp and ssbb), 2.60-2.80 (m, 4 H, -CH2-SS-CH2-), 2.90-3.55 
(m, 40 H, -CH2- Tp and ssbb, εH tryptophane), 4.10-4.60 (m, 5 H, αH tryptophanes and leucines), 7.00-7.65 (m, 
10 H, aromatic H tryptophane). 
 
 
 
 
